Results 121 to 130 of about 23,326 (220)
Introduction. Acromegaly is an endocrine pathology characterized by the overproduction of human growth hormone. The present study aimed to analyze three-dimensional speckle-tracking echocardiography (3DSTE)-derived tricuspid annular (TA) properties in ...
Attila Nemes +6 more
doaj +1 more source
Growth Differentiation Factor 15 in Patients with Acromegaly: A Case–Control Study
Objective: It was previously shown that the levels of several biomarkers increase due to acromegaly disease-related inflammation, and some markers are parallel to the disease’s activity.
Serdar Kayıhan +11 more
core +1 more source
Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients [PDF]
Objective: To investigate the efficacy of the dopamine agonist cabergoline in uncontrolled acromegaly despite long-acting somatostatin analog (SSA). Methods: Thirty-five patients with acromegaly who were followed up in the department of endocrinology ...
Meriç Coşkun +13 more
core +1 more source
[What is the value of determining immunoreactive GHRH in acromegaly?]
Acromegaly is usually due to autonomous, excessive secretion of growth hormone from a pituitary adenoma. One would expect growth hormone-releasing factor (GHRH) in these patients to be suppressed.
Bürgi, U +3 more
core
Acromegaly - a neuroendocrine pathology, caused by chronic overproduction of growth hormone. Chronic overproduction of somatotropin and insulin growth factor (IGF) is clinically expressed in gigantism or acromegaly.
E L Soyustova
core +1 more source
Communication practices and awareness of resources for acromegaly patients among endocrinologists
Susan Polanco-Briceno,1 Daniel Glass,1 Cindy Plunkett2 1Deerfield Institute, New York, NY, USA; 2Department of Internal Medicine, Metabolism Endocrinology & Diabetes (MEND), University of Michigan, Ann Arbor, MI, USA Purpose: This study was ...
Glass D, Polanco-Briceno S, Plunkett C
core
Bromocriptine-associated ototoxicity [PDF]
Three patients treated with bromocriptine for chronic hepatic encephalopathy showed audiometric evidence of bilateral sensori-neural hearing-loss. Audiometrically, the hearing improved in all three patients when the bromocriptine dosage was reduced, thus
Morgan, MY, Ballantyne, J, Lanthier, PL
core
Cynthia Plunkett, Ariel L BarkanDivision of Endocrinology, University of Michigan Medical Center, Ann Arbor, MI, USAAbstract: Patients with acromegaly (a condition of chronic growth hormone hypersecretion by a pituitary adenoma) often require ...
Plunkett C, Barkan AL
core
Management of Diabetes Mellitus in Acromegaly and Cushing’s Disease with Focus on Pasireotide Therapy: A Narrative Review [PDF]
Michelantonio De Fano, Alberto Falorni, Massimo Malara, Francesca Porcellati, Carmine Giuseppe Fanelli Department of Medicine and Surgery, Endocrine and Metabolic Sciences Section, University of Perugia, Perugia, ItalyCorrespondence: Michelantonio De ...
De Fano M +4 more
core

